Notice of Completion of Application for Partial Change Approval of AKUUGO🄬 Suspension for Intracranial Implantation

Keita Mori, Representative Director and President of SanBio, Appointed Chairman of Samurai Biotech Association

The Results of the Third Commercial Production Run to Meet the Approval Conditions for the Shipment of AKUUGO🄬 Suspension for Intracranial Implantation

On April 7, NeurologyLive published an interview with Dr. Peter McAllister regarding the final analysis of the Phase 2 STEMTRA trial.

Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio, publishes report in the leading medical journal, Stroke

Sawaguchi, Head of Japan Regulatory Affairs & Quality Compliance Japan, will speak at 【Regenerative Medicine Seminar 2024】“Development of Regenerative Medicine Products: Recent Trends in Regenerative Medicine and Other Related Issues” (Vol.5: Quality in Regenerative Medicine Products)” hosted by the Clinical and Translational Research Center (CTR) Keio University Hospital

MORI, President & CEO, will be a panelist at “Navigating Biopharma Innovation Across the Pacific” hosted by the U.S. Embassy and the Japan Society of Northern California on November 11

Presentation of Phase 2 STEMTRA Trial Results at The 14th World Congress on Brain Injury